{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T04:50:08Z","timestamp":1789275008290,"version":"build-2803163510"},"reference-count":47,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"NINDS\/NIH","award":["R01NS040068"],"award-info":[{"award-number":["R01NS040068"]}]},{"name":"NINDS\/NIH","award":["U01NS103475"],"award-info":[{"award-number":["U01NS103475"]}]},{"name":"NINDS\/NIH","award":["U01NS105509"],"award-info":[{"award-number":["U01NS105509"]}]},{"DOI":"10.13039\/100005725","name":"CHDI","doi-asserted-by":"publisher","award":["A3917"],"award-info":[{"award-number":["A3917"]}],"id":[{"id":"10.13039\/100005725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005725","name":"CHDI","doi-asserted-by":"publisher","award":["A6266"],"award-info":[{"award-number":["A6266"]}],"id":[{"id":"10.13039\/100005725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Huntington\u2019s disease (HD) is characterized by progressive striatal atrophy and complex proteomic changes in the central nervous system. Using the ultrasensitive Next-Gen Ultra-Sensitive Immunoassay (NULISA) proteomic platform, we analyzed cerebrospinal fluid (CSF) from 88 persons with HD to dissect the biological correlates of gray matter loss. Our findings reveal a distinct \u201cTwo-Track\u201d model of pathology. The first track, marked by the axonal damage protein neurofilament light chain (NEFL), showed a strong inverse correlation with putamen volume (Pearson r = \u22120.53, p &lt; 0.001), reinforcing its utility as a proxy for structural neurodegeneration. The second track was defined by a positive association between the immune regulator TNFRSF8 (CD30) and putamen volume (Pearson r = 0.36, p &lt; 0.001), reflecting a decline in active immune-regulatory signaling as striatal atrophy advances. Given its established role in immune modulation, TNFRSF8 was pre-specified for follow-up to further interrogate this neuro-immune axis. Crucially, TNFRSF8 maintained an independent association with striatal volume (Beta = 0.24, p = 0.008) even after controlling for NEFL, genetic burden (CAG-Age Product score), and sex. Supplementary analyses confirmed that this structural\u2013immune axis is localized specifically to the striatum\u2014showing no association with generic structural control regions\u2014and is driven by CAG repeat length rather than chronological aging. Furthermore, bidirectional mediation analysis supported an atrophy-driven model, where striatal volume statistically mediates the relationship between genetic burden and downstream immune dysregulation (p = 0.010). These results demonstrate that maladaptive immune signaling is a distinct pathological correlate in HD, separable from general cytoskeletal damage. This dual-axis framework warrants evaluation in larger longitudinal and interventional studies to guide future biomarker-driven patient stratification and target engagement.<\/jats:p>","DOI":"10.3390\/ijms27052384","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T13:11:36Z","timestamp":1772629896000},"page":"2384","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A Two-Track Model of Huntington\u2019s Disease Pathology: Striatal Atrophy Mediates Maladaptive Immune Dysregulation"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8523-3361","authenticated-orcid":false,"given":"H. Jeremy","family":"Bockholt","sequence":"first","affiliation":[{"name":"Center for Translational Research in Neuroimaging and Data Science (TReNDS), Georgia State University, Atlanta, GA 30303, USA"},{"name":"School of Electrical and Computer Engineering, Georgia Institute of Technology, Atlanta, GA 30332, USA"},{"name":"Department of Neurology, Emory University, Atlanta, GA 30322, USA"},{"name":"Department of Neurology, University of Wisconsin\u2013Madison, Madison, WI 53706, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan D.","family":"Clemsen","sequence":"additional","affiliation":[{"name":"Center for Translational Research in Neuroimaging and Data Science (TReNDS), Georgia State University, Atlanta, GA 30303, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley T.","family":"Baker","sequence":"additional","affiliation":[{"name":"Center for Translational Research in Neuroimaging and Data Science (TReNDS), Georgia State University, Atlanta, GA 30303, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vince D.","family":"Calhoun","sequence":"additional","affiliation":[{"name":"Center for Translational Research in Neuroimaging and Data Science (TReNDS), Georgia State University, Atlanta, GA 30303, USA"},{"name":"School of Electrical and Computer Engineering, Georgia Institute of Technology, Atlanta, GA 30332, USA"},{"name":"Department of Neurology, Emory University, Atlanta, GA 30322, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0983-228X","authenticated-orcid":false,"given":"Jane S.","family":"Paulsen","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Wisconsin\u2013Madison, Madison, WI 53706, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Tong, H., Yang, T., Xu, S., Li, X., Liu, L., Zhou, G., Yang, S., Yin, S., Li, X.J., and Li, S. (2024). Huntington\u2019s Disease: Complex Pathogenesis and Therapeutic Strategies. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25073845"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1007\/s13311-012-0112-2","article-title":"Huntington\u2019s disease and the striatal medium spiny neuron: Cell-autonomous and non-cell-autonomous mechanisms of disease","volume":"9","author":"Ehrlich","year":"2012","journal-title":"Neurotherapeutics"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1002\/mds.22601","article-title":"Motor abnormalities in premanifest persons with Huntington\u2019s disease: The PREDICT-HD study","volume":"24","author":"Biglan","year":"2009","journal-title":"Mov. Disord."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"127","DOI":"10.3233\/JHD-170236","article-title":"Predict-HD Investigators of the Huntington Study Group. Dynamic Prediction of Motor Diagnosis in Huntington\u2019s Disease Using a Joint Modeling Approach","volume":"6","author":"Li","year":"2017","journal-title":"J. Huntingt. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1136\/jnnp.2007.128728","article-title":"Detection of Huntington\u2019s disease decades before diagnosis: The Predict-HD study","volume":"79","author":"Paulsen","year":"2008","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Roze, E., Cahill, E., Martin, E., Bonnet, C., Vanhoutte, P., Betuing, S., and Caboche, J. (2011). Huntington\u2019s Disease and Striatal Signaling. Front. Neuroanat., 5.","DOI":"10.3389\/fnana.2011.00055"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1002\/mds.26013","article-title":"Magnetic resonance imaging striatal volumes: A biomarker for clinical trials in Huntington\u2019s disease","volume":"29","author":"Aylward","year":"2014","journal-title":"Mov. Disord."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.it.2015.04.007","article-title":"The choreography of neuroinflammation in Huntington\u2019s disease","volume":"36","author":"Crotti","year":"2015","journal-title":"Trends Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Rodrigues, F.B., Byrne, L.M., McColgan, P., Robertson, N., Tabrizi, S.J., Zetterberg, H., and Wild, E.J. (2016). Cerebrospinal Fluid Inflammatory Biomarkers Reflect Clinical Severity in Huntington\u2019s Disease. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0163479"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"7238","DOI":"10.1038\/s41467-023-42834-x","article-title":"NULISA: A proteomic liquid biopsy platform with attomolar sensitivity and high multiplexing","volume":"14","author":"Feng","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Ghazaleh, N., Houghton, R., Palermo, G., Schobel, S.A., Wijeratne, P.A., and Long, J.D. (2021). Ranking the Predictive Power of Clinical and Biological Features Associated With Disease Progression in Huntington\u2019s Disease. Front. Neurol., 12.","DOI":"10.3389\/fneur.2021.678484"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Paulsen, J.S., Long, J.D., Johnson, H.J., Aylward, E.H., Ross, C.A., Williams, J.K., Nance, M.A., Erwin, C.J., Westervelt, H.J., and Harrington, D.L. (2014). Clinical and Biomarker Changes in Premanifest Huntington Disease Show Trial Feasibility: A Decade of the PREDICT-HD Study. Front. Aging Neurosci., 6.","DOI":"10.3389\/fnagi.2014.00078"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"eabc2888","DOI":"10.1126\/scitranslmed.abc2888","article-title":"Mutant huntingtin and neurofilament light have distinct longitudinal dynamics in Huntington\u2019s disease","volume":"12","author":"Rodrigues","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"fcac309","DOI":"10.1093\/braincomms\/fcac309","article-title":"Cerebrospinal fluid biomarkers for assessing Huntington disease onset and severity","volume":"4","author":"Caron","year":"2022","journal-title":"Brain Commun."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s12026-013-8464-1","article-title":"CD30: From basic research to cancer therapy","volume":"57","author":"Muta","year":"2013","journal-title":"Immunol. Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e603","DOI":"10.1038\/bcj.2017.85","article-title":"Understanding CD30 biology and therapeutic targeting: A historical perspective providing insight into future directions","volume":"7","author":"Pileri","year":"2017","journal-title":"Blood Cancer J."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1207\/s15327906mbr1503_7","article-title":"Testing Pattern Hypotheses On Correlation Matrices: Alternative Statistics And Some Empirical Results","volume":"15","author":"Steiger","year":"1980","journal-title":"Multivar. Behav. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1080\/01621459.2013.823775","article-title":"Estimation and Accuracy after Model Selection","volume":"109","author":"Efron","year":"2014","journal-title":"J. Am. Stat. Assoc."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1084\/jem.20080178","article-title":"A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington\u2019s disease","volume":"205","author":"Bjorkqvist","year":"2008","journal-title":"J. Exp. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"541259","DOI":"10.1155\/2013\/541259","article-title":"The role of the immune system in Huntington\u2019s disease","volume":"2013","author":"Ellrichmann","year":"2013","journal-title":"Clin. Dev. Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Li, X., Tong, H., Xu, S., Zhou, G., Yang, T., Yin, S., Yang, S., Li, X., and Li, S. (2024). Neuroinflammatory Proteins in Huntington\u2019s Disease: Insights into Mechanisms, Diagnosis, and Therapeutic Implications. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms252111787"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1093\/brain\/awm044","article-title":"Microglial activation in presymptomatic Huntington\u2019s disease gene carriers","volume":"130","author":"Tai","year":"2007","journal-title":"Brain"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Yang, H.M., Yang, S., Huang, S.S., Tang, B.S., and Guo, J.F. (2017). Microglial Activation in the Pathogenesis of Huntington\u2019s Disease. Front. Aging Neurosci., 9.","DOI":"10.3389\/fnagi.2017.00193"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/nrd3930","article-title":"Clinical targeting of the TNF and TNFR superfamilies","volume":"12","author":"Croft","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3233\/JHD-210475","article-title":"Standardizing the CAP Score in Huntington\u2019s Disease by Predicting Age-at-Onset","volume":"11","author":"Warner","year":"2022","journal-title":"J. Huntingt. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1177\/0013164417743003","article-title":"Time and Other Considerations in Mediation Design","volume":"78","author":"Cain","year":"2018","journal-title":"Educ. Psychol. Meas."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1207\/s15327906mbr3901_4","article-title":"Confidence Limits for the Indirect Effect: Distribution of the Product and Resampling Methods","volume":"39","author":"Mackinnon","year":"2004","journal-title":"Multivar. Behav. Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1037\/1082-989X.12.1.23","article-title":"Bias in cross-sectional analyses of longitudinal mediation","volume":"12","author":"Maxwell","year":"2007","journal-title":"Psychol. Methods"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.neulet.2007.02.053","article-title":"Plasma neurofilament heavy chain levels in Huntington\u2019s disease","volume":"417","author":"Wild","year":"2007","journal-title":"Neurosci. Lett."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s00441-017-2626-8","article-title":"Myeloperoxidase-immunoreactive cells are significantly increased in brain areas affected by neurodegeneration in Parkinson\u2019s and Alzheimer\u2019s disease","volume":"369","author":"Gellhaar","year":"2017","journal-title":"Cell Tissue Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1179\/1743132812Y.0000000073","article-title":"Oxidative stress and inflammation biomarkers in the blood of patients with Huntington\u2019s disease","volume":"34","author":"Tasset","year":"2012","journal-title":"Neurol. Res."},{"key":"ref_32","first-page":"666","article-title":"Clinical utility of serum levels of ubiquitin C-terminal hydrolase as a biomarker for severe traumatic brain injury","volume":"70","author":"Mondello","year":"2012","journal-title":"Neurosurgery"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/CCM.0b013e3181b788ab","article-title":"Ubiquitin C-terminal hydrolase is a novel biomarker in humans for severe traumatic brain injury","volume":"38","author":"Papa","year":"2010","journal-title":"Crit. Care Med."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Kinnunen, K.M., Mullin, A.P., Pustina, D., Turner, E.C., Burton, J., Gordon, M.F., Scahill, R.I., Gantman, E.C., Noble, S., and Romero, K. (2021). Recommendations to Optimize the Use of Volumetric MRI in Huntington\u2019s Disease Clinical Trials. Front. Neurol., 12.","DOI":"10.3389\/fneur.2021.712565"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3233\/JHD-240044","article-title":"Huntington\u2019s Disease Nomenclature Working Group. Towards Standardizing Nomenclature in Huntington\u2019s Disease Research","volume":"13","author":"DiFiglia","year":"2024","journal-title":"J. Huntingt. Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1002\/psp4.12097","article-title":"Modeling Variability in the Progression of Huntington\u2019s Disease A Novel Modeling Approach Applied to Structural Imaging Markers from TRACK-HD","volume":"5","author":"Warner","year":"2016","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"117012","DOI":"10.1016\/j.neuroimage.2020.117012","article-title":"FastSurfer\u2014A fast and accurate deep learning based neuroimaging pipeline","volume":"219","author":"Henschel","year":"2020","journal-title":"Neuroimage"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e089661","DOI":"10.1002\/alz.089661","article-title":"NINDS-supported biospecimen repositories: BioSEND and NHCDR","volume":"20","author":"Price","year":"2025","journal-title":"Alzheimers Dement."},{"key":"ref_39","unstructured":"Alamar Biosciences (2026, February 26). NULISAseq\u2122 CNS Disease Panel 120. Available online: https:\/\/alamarbio.com\/nulisaseq-cns-disease-panel\/."},{"key":"ref_40","unstructured":"Alamar Biosciences (2026, February 26). NULISAseq\u2122 Inflammation Panel 250. Available online: https:\/\/alamarbio.com\/products-and-services\/nulisa-inflammation-panel\/."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J. R. Stat. Soc. Ser. B (Methodol.)"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"558","DOI":"10.4097\/kja.19087","article-title":"Multicollinearity and misleading statistical results","volume":"72","author":"Kim","year":"2019","journal-title":"Korean J. Anesthesiol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"533","DOI":"10.3945\/ajcn.115.113498","article-title":"Best (but oft-forgotten) practices: Checking assumptions concerning regression residuals","volume":"102","author":"Barker","year":"2015","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"486","DOI":"10.5812\/ijem.3505","article-title":"Normality tests for statistical analysis: A guide for non-statisticians","volume":"10","author":"Ghasemi","year":"2012","journal-title":"Int. J. Endocrinol. Metab."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1214\/12-AOS978","article-title":"Perturbation and Scaled Cook\u2019s Distance","volume":"40","author":"Zhu","year":"2012","journal-title":"Ann. Stat."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1037\/a0020761","article-title":"A general approach to causal mediation analysis","volume":"15","author":"Imai","year":"2010","journal-title":"Psychol. Methods"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1177\/1088868314542878","article-title":"Statistical approaches for enhancing causal interpretation of the M to Y relation in mediation analysis","volume":"19","author":"MacKinnon","year":"2015","journal-title":"Pers. Soc. Psychol. Rev."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/5\/2384\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T13:14:52Z","timestamp":1772630092000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/5\/2384"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,4]]},"references-count":47,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["ijms27052384"],"URL":"https:\/\/doi.org\/10.3390\/ijms27052384","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,4]]}}}